Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada

PharmacoEconomics

Volumn 25, Issue 3, 2007, Pages 253-266

  Grima, Daniel T ^a   Thompson, Melissa F ^a   Sauriol, Luc ^b  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b Sanofi Aventis   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; DRUG COST; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; STROKE;

ANALYSIS OF VARIANCE; CANADA; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; TREATMENT OUTCOME;

EID: 33847691924     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725030-00007     Document Type: Article

References (55)

1. Ohinmaa A, Jacobs P, Simpson S, et al. The projection of prevalence and cost of diabetes in Canada: 2000 to 2016. Can J Diabetes 2004; 28 (2): 116-23
2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27 Suppl. 2: S1-152
3. American Diabetes Association. American summary of revisions for the 2004 clinical practice recommendations. Diabetes Care 2004; 27 Suppl. 1: S3
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14): 977-86
6. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44 (8): 968-83
7. Cryer PE. Banting lecture: hypoglycaemia. The limiting factor in the management of IDDM. Diabetes 1994; 43 (11): 1378-89
8. Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Clev Clin J Med 2004; 71 (4): 335-42
9. Green L, Feher M, Catalan J. Fear and phobias in people with diabetes. Diabetes Metab Res Rev 2000; 16 (4): 287-93
10. ter Braak EW, Appelman AM, van de Laak M, et al. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000; 23 (10): 1467-71
11. Clarke WL, Gonder-Frederick A, Snyder AL, et al. Maternal fear of hypoglycemia in their children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 1998; 11 Suppl. 1: 189-94
12. Gonder-Frederick L, Cox D, Kovatchev B, et al. The psychosocial impact of severe hypoglycemic episodes on spouses of patients with IDDM. Diabetes Care 1997; 20 (10): 1543-6
13. Marrero DG, Guare JC, Vandagriff JL, et al. Fear of hypoglycemia in the parents of children and adolescents with diabetes: maladaptive or healthy response? Diabetes Educ 1997; 23 (3): 281-6
14. Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol 1992; 11 (2): 135-8
15. Polonsky WH, Davis CL, Jacobson AM, et al. Hyperglycaemia, hypoglycaemia, and blood glucose control in diabetes: symptom perceptions and treatment strategies. Diabet Med 1992; 9 (2): 120-5
16. Polonsky WH, Davis CL, Jacobson AM, et al. Correlates of hypoglycemic fear in type I and type II diabetes mellitus. Health Psychol 1992; 11 (3): 199-202
17. Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987; 10 (5): 617-21
18. Harris SB, Ekoe JM, Zdanowicz Y, et al. Glycemic control and morbidity in the Canadian primary care setting: results of the diabetes in Canada evaluation study. Diabetes Res and Clin Pract 2005; 70 (1): 90-7
19. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23 (5): 644-9
20. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49 (12): 2142-8
21. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28 (4): 950-5
22. Riddle MC, Rosenstock J, Gerich J, et al. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26 (11): 3080-6
23. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabet Med 2003; 20 (7): 545-51
24. Yki-Jarvinen H, Johnson E, Haring H-U, et al. The relationship between HbA1c, fasting blood glucose (FBG) and hypoglycemia using insulin glargine versus NPH insulin: a meta-regression analysis in type 2 diabetes [abstract 2216]. Diabetes Metab 2003; 29
25. Fischer JS, McLaughlin T, Loza L, et al. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 2004; 20 (11): 1703-10
26. Schreiber SA, Russmann A. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice. Curr Med Res Opin 2006; 22 (2): 335-41
27. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes 2005; 28 (2): 254-9
28. Davies M, Storms F, Shutler S, et al. ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28 (6): 1282-8
29. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21 (11): 1213-20
30. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006; 23 (3): 285-92
31. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26 (5): 1490-6
32. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005; 35 (9): 536-42
33. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes: the European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000; 23 (2): 157-62
34. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53
35. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002; 162 (15): 1689-94
36. Statistics Canada. 2006 life tables, Canada, Provinces and Territories 2000-2002. Ottawa: Statistics Canada Catalogue No. 84-537-X16
37. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124 (1 Pt 2): 136-45
38. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355 (9200): 253-9
39. Booth G, Rothwell D, Fung K, et al. Diabetes and cardiac disease. In: Hux JE, Booth GL, Slaughter PM, et al. (editors). Diabetes in Ontario: an ICES practice atlas. Toronto (ON): Institute for Clinical Evaluative Sciences, 2003: 5.95-5.112
40. Kapral M, Rothwell D, Fung K, et al. Diabetes and stroke. In: Hux JE, Booth GL, Slaughter PM, et al. (editors). Diabetes in Ontario: an ICES practice atlas. Toronto (ON): Institute for Clinical Evaluative Sciences, 2003: 7.151-7.164
41. Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000; 43 (1): 13-26
42. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996; 276 (17): 1409-15
43. Data on file, sanofi-aventis Canada Inc. 2004
44. Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002; 20 Suppl. 1: 31-42
45. O JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003; 3 (1): 7
46. Bentkover JD, Stewart EJ, Ignaszewski A, et al. New technologies and potential cost savings related to morbidity and mortality reduction in class III/IV heart failure patients in Canada. Int J Cardiol 2003; 88 (1): 33-41
47. Data on file, Aventis Pharma Canada, 2004
48. Liste de médicaments publiée par la Regie de l'assurance maladie du Québec. October 2003 [online]. Available from URL: http://www.ra mq.gouv.qc.ca/fr/professionnels/listmed/lm_tdmf_originale.shtml [Accessed 2004 Nov 7]
49. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22: 1125-36
50. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25 (12): 2238-43
51. Egger M, Davey Smith G, Stettler C, et al. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997; 14 (11): 919-28
52. Reichard P, Pihl M, Rosenqvist U, et al. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996; 39 (12): 1483-8
53. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473-81
54. Fritsche A, Schweitzer MA, Haring HU, et al. 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003; 138 (12): 952-9
55. Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35 (3): 189-96